At Fall Clinical 2026, Glynis Ablon, MD, recommends body dysmorphic disorder screening and systematic documentation in aesthetics, plus early combination therapy for multifactorial alopecia.
Feature|Articles|September 24, 2026
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Advertisement
Advertisement
September marks National Alopecia Areata Awareness Month, as designated by the National Alopecia Areata Foundation, making hair loss a common topic in visits this time of year.¹ Much of that public conversation centers on
Related to this article
This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Advertisement
Advertisement